Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
Contineum Therapeutics reported that its Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in major depressive disorder did not meet its primary efficacy endpoint. The trial measured improvement from baseline in MADRS total score at Day 5 versus placebo; the drug was well-tolerated with no new safety signals, and J&J is still evaluating prespecified exploratory endpoints to inform next steps.
Key figures
- Drug Name
- JNJ-5120/PIPE-307
- Phase Of Trial
- Phase 2
- Nct id
- NCT06785012
- Safety
- well-tolerated, no new safety signals
- Indication
- major depressive disorder
- Trial name
- MOONLIGHT-1
- Trial design
- randomized, double-blind, multicenter, placebo-controlled proof-of-concept
- Primary endpoint
- improvement from baseline in MADRS total score at Day 5 vs placebo
- Primary endpoint result
- not met
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.